- Products & Projects
- Questions & Answers
- Press & Papers
- Know NeuroVigil
- Ask NeuroVigil
- Search
The iBrain
Open EEG Database
Remembering Alzheimer's
Diagnostics
SPEARS
What we do
Sleep Apnea
Drugs & Sleep
Safety & Sleep
EEG Analysis
Recent News
Beginnings
Events & Talks
Business Awards
Member Honors
Our Philosophy
NeuroVigil Team
Leadership
The Board
Consultants
Volunteers
Collaborators
Email NeuroVigil
PHILOSOPHY
NeuroVigil, Inc. is dedicated to the betterment of the human condition
by merging non-invasive wireless brain recording technology with advanced computational analysis techniques. The company has developed proprietary technology which leverages the dynamic oscillations produced during sleep in order to systematically scan the brain for signs of pathologic activity years in advance of cognitive or behavioral symptoms.
The NeuroVigil team is comprised of Dr. Philip low, Founder and CEO, as well as polysomnographers, engineers with industry training, Fortune 500 CEOs and business experts in product development, wireless technology and the transportation industry, six members of the National Academy of Science, and four Nobel laureates.
The company is currently in negotiation with drug developers seeking to scan new drugs for pathological effects on brain activity.
NeuroVigil, Inc. is dedicated to the betterment of the human condition
by merging non-invasive wireless brain recording technology with advanced computational analysis techniques. The company has developed proprietary technology which leverages the dynamic oscillations produced during sleep in order to systematically scan the brain for signs of pathologic activity years in advance of cognitive or behavioral symptoms.
The NeuroVigil team is comprised of Dr. Philip low, Founder and CEO, as well as polysomnographers, engineers with industry training, Fortune 500 CEOs and business experts in product development, wireless technology and the transportation industry, six members of the National Academy of Science, and four Nobel laureates.
The company is currently in negotiation with drug developers seeking to scan new drugs for pathological effects on brain activity.